# VERA catalysts: Vera Therapeutics, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/vera/catalysts

> Vera Therapeutics, Inc. (VERA) has 2 upcoming catalysts. The next is the TRUTAKNA (atacicept) primary completion, November 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Vera Therapeutics, Inc. |
| Ticker | VERA (Nasdaq) |
| SEC CIK | 1831828 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/vera |

## Cash runway

Cash $384.0M as of 2026-09-30; quarterly burn $99.2M; about 11.6 months of runway at that rate (XBRL company facts, accession 0001193125-26-449826).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jan 2023 | [TRUTAKNA (atacicept) topline data readout](https://sec-api.dev/pdufa/atacicept) | VERA |  | completed, positive | "We reported positive topline 24-week results in January 2023, 36-week results in June 2023, and 96-week results in October 2024 from the ORIGIN 2b trial." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1831828/000119312526077442/vera-20251231.htm)) |
| Jan 2023 | [Vera Therapeutics, Inc. topline data readout](https://sec-api.dev/companies/vera/catalysts) | VERA |  | completed, positive | "We reported positive topline 24-week results in January 2023, 36-week results in June 2023, and 96-week results in October 2024 from the Phase 2b ORIGIN trial." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1831828/000095017025029969/vera-20241231.htm)) |
| February 26, 2025 | [Vera Therapeutics, Inc. earnings report](https://sec-api.dev/companies/vera/catalysts) | VERA |  | completed | "Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1831828/000095017025027337/vera-ex99_1.htm)) |
| Q2 2025 | [TRUTAKNA (atacicept) topline data readout](https://sec-api.dev/pdufa/atacicept) | VERA |  | scheduled | "With Phase 3 topline results expected in the second quarter of 2025, if positive, we expect to submit a biologics license application (BLA) for atacicept in IgAN to the FDA in the second half of 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1831828/000095017025029969/vera-20241231.htm)) |
| May 6, 2025 | [Vera Therapeutics, Inc. earnings report](https://sec-api.dev/companies/vera/catalysts) | VERA |  | completed | "BRISBANE, Calif., May 6, 2025 - Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights and financial results for the first quarter ended March 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1831828/000095017025063975/vera-ex99_1.htm)) |
| May 15, 2025 | [TRUTAKNA (atacicept) primary completion](https://sec-api.dev/pdufa/atacicept) | VERA | IgA Nephropathy; Berger Disease | completed | "NCT04716231 (Atacicept in Subjects With IgA Nephropathy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-05-15 (ACTUAL); Lead Sponsor Vera Therapeutics, Inc.; Results First Posted 2026-10-01." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04716231)) |
| Aug 2025 | [TRUTAKNA (atacicept) trial start](https://sec-api.dev/pdufa/atacicept) | VERA |  | completed | "Due to the positive results of the ORIGIN program, in August 2025 we initiated the PIONEER trial, a global, open label, Phase 2 basket trial evaluating the safety and initial signals of efficacy of atacicept in an expanded cohort of IgAN patients and other autoimmune-mediated glomerular diseases." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1831828/000119312526077442/vera-20251231.htm)) |
| August 5, 2025 | [Vera Therapeutics, Inc. earnings report](https://sec-api.dev/companies/vera/catalysts) | VERA |  | completed | "BRISBANE, Calif., August 5, 2025 - Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights and financial results for the second quarter ended June 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1831828/000095017025102399/vera-ex99_1.htm)) |
| Q4 2025 | [TRUTAKNA (atacicept) NDA/BLA submission](https://sec-api.dev/pdufa/atacicept) | VERA |  | scheduled | "On track to submit a Biologics License Application (BLA) for accelerated approval of atacicept to U.S. FDA in Q4 2025; potential commercial launch in 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1831828/000095017025102399/vera-ex99_1.htm)) |
| Nov 2025 | [TRUTAKNA (atacicept) NDA/BLA submission](https://sec-api.dev/pdufa/atacicept) | VERA | with IgAN | completed | "In November 2025, we submitted a Biologics License Application (BLA) for atacicept for the treatment of adults with IgAN to the U.S. Food and Drug Administration (FDA) through the Accelerated Approval Program." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1831828/000119312526212143/vera-20260331.htm)) |
| November 5, 2025 | [Vera Therapeutics, Inc. earnings report](https://sec-api.dev/companies/vera/catalysts) | VERA |  | completed | "BRISBANE, Calif., November 5, 2025 - Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights and financial results for the third quarter ended September 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1831828/000119312525265799/vera-ex99_1.htm)) |
| Jan 2026 | [TRUTAKNA (atacicept) NDA/BLA acceptance](https://sec-api.dev/pdufa/atacicept) | VERA |  | completed | "In January 2026, the Company achieved a specified regulatory milestone and paid $15.0 million to Ares upon acceptance of the Company's Biologics License Application (BLA) for TRUTAKNA for treatment of IgAN by the FDA." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1831828/000119312526449826/vera-20260930.htm)) |
| February 26, 2026 | [Vera Therapeutics, Inc. earnings report](https://sec-api.dev/companies/vera/catalysts) | VERA |  | completed | "Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1831828/000119312526073421/vera-ex99_1.htm)) |
| May 7, 2026 | [Vera Therapeutics, Inc. earnings report](https://sec-api.dev/companies/vera/catalysts) | VERA |  | completed | "Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1831828/000119312526210351/vera-ex99_1.htm)) |
| Jul 2026 | [TRUTAKNA (atacicept) FDA approval](https://sec-api.dev/pdufa/atacicept) | VERA | primary IgAN | completed, approved | "TRUTAKNA, our first approved product, received accelerated approval from the FDA in July 2026 to reduce proteinuria in adults with primary IgAN who are at risk for disease progression." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1831828/000119312526449826/vera-20260930.htm)) |
| July 7, 2026 | [TRUTAKNA (atacicept) PDUFA date](https://sec-api.dev/pdufa/atacicept) | VERA |  | scheduled | "FDA granted Priority Review to the atacicept BLA for the treatment of IgAN in adults, and assigned a PDUFA target action date of July 7, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1831828/000119312526210351/vera-ex99_1.htm)) |
| July 7, 2026 | [Trutakna (atacicept-vymj) FDA approval](https://sec-api.dev/pdufa/atacicept-vymj) | VERA |  | completed, approved | "Trutakna \| atacicept-vymj \| 7/7/2026 \| To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk for disease progression" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)) |
| August 10, 2026 | [Vera Therapeutics, Inc. earnings report](https://sec-api.dev/companies/vera/catalysts) | VERA |  | completed | "Vera Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1831828/000119312526342335/vera-ex99_1.htm)) |
| September 22, 2026 | [TRUTAKNA (atacicept) primary completion](https://sec-api.dev/pdufa/atacicept) | VERA | IgA Nephropathy (IgAN); Berger Disease | completed | "NCT07020923 (Monthly Dosing of Atacicept in IgAN): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09-22 (ACTUAL); Lead Sponsor Vera Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07020923)) |
| Sep to Dec 2026 | [TRUTAKNA (atacicept) topline data readout](https://sec-api.dev/pdufa/atacicept) | VERA | IgA Nephropathy (IgAN); Berger Disease | scheduled | "NCT07020923 (Monthly Dosing of Atacicept in IgAN): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09-22 (ACTUAL); Lead Sponsor Vera Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07020923)) |
| Q4 2026 | [TRUTAKNA (atacicept) NDA/BLA submission](https://sec-api.dev/pdufa/atacicept) | VERA |  | scheduled | "Pending these results, the Company plans to submit a supplemental Biologics License Application for full approval of atacicept in the fourth quarter of 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1831828/000119312526252475/vera-20260602.htm)) |
| October 1, 2026 | [TRUTAKNA (atacicept) topline data readout](https://sec-api.dev/pdufa/atacicept) | VERA | IgA Nephropathy; Berger Disease | completed | "NCT04716231 (Atacicept in Subjects With IgA Nephropathy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-05-15 (ACTUAL); Lead Sponsor Vera Therapeutics, Inc.; Results First Posted 2026-10-01." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04716231?tab=results)) |
| November 5, 2026 | [Vera Therapeutics, Inc. earnings report](https://sec-api.dev/companies/vera/catalysts) | VERA |  | completed | "Vera Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1831828/000119312526449780/vera-ex99_1.htm)) |
| November 2027 | [TRUTAKNA (atacicept) primary completion](https://sec-api.dev/pdufa/atacicept) | VERA | pMN; IgAN; Nephrotic Syndrome | scheduled | "NCT06983028 (Atacicept in Multiple Glomerular Diseases): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor Vera Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06983028)) |
| Nov 2027 to Feb 2028 | [TRUTAKNA (atacicept) topline data readout](https://sec-api.dev/pdufa/atacicept) | VERA | pMN; IgAN; Nephrotic Syndrome | scheduled | "NCT06983028 (Atacicept in Multiple Glomerular Diseases): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11 (ESTIMATED); Lead Sponsor Vera Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06983028)) |

## Drugs

- [TRUTAKNA (atacicept)](https://sec-api.dev/pdufa/atacicept): primary igan, with igan, IgA Nephropathy, pMN, IgA Nephropathy (IgAN)
- [Trutakna (atacicept-vymj)](https://sec-api.dev/pdufa/atacicept-vymj): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/vera/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "VERA catalysts: Vera Therapeutics, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/vera/catalysts

```bibtex
@misc{secapidev_companies_vera_catalysts_20261116,
  title        = {VERA catalysts: Vera Therapeutics, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/vera/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_vera_catalysts_20261116","title":"VERA catalysts: Vera Therapeutics, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/vera/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
